Isomorphic Labs in talks for $5B round at $50B valuation
TL;DR
- Isomorphic Labs is in early-stage talks to raise roughly $5 billion at a valuation of about $50 billion, Bloomberg reports.
- The Alphabet-owned DeepMind spinout closed a $2.1 billion round only about five months ago backed by Alphabet, Thrive Capital and the UK Sovereign AI Fund.
- Despite attracting billions in investment, Isomorphic has yet to test its own drug candidates in humans.
Alphabet-owned Isomorphic Labs is in talks to raise roughly $5 billion at a valuation of about $50 billion, Bloomberg reported. The discussions are early-stage and the investors expected to back the deal were not specified.
The number sits against a company that, in Bloomberg's own words, "has yet to test its own drug candidates in humans." The DeepMind spinout, led by Nobel Prize-winning scientist Sir Demis Hassabis, uses AI to design potential medicines on top of AlphaFold, with partnerships at Eli Lilly and Novartis and a stated focus on cancer and immune disorders.
Pricing has moved fast. Isomorphic closed a $2.1 billion Series B round in May backed by Alphabet, Thrive Capital and the UK Sovereign AI Fund. A $50 billion mark would reprice the company roughly five months after that raise. The financing has not closed and details could still change.
It also lands into a visibly mixed moment for Silicon Valley's AI-drug thesis, with pharma CEOs publicly pushing back on the cure-everything pitch even as the capital keeps arriving.
Originally reported by bloomberg.com
Read the original article →Original headline: Isomorphic Labs in talks to raise ~$5B at ~$50B valuation, more than 20x its May round